found this post that Joe had previously made....sounds right on target.
Trading strategy from the 1930s that hedge funders don’t want you to know about.
It takes a while for a hedge pro to accumulate a position in advance of a big move as buying too many shares at once would cause the price to rise too quickly. The preparation of an important move in the market takes a considerable time. A large operator or investor acting singly cannot often, in a single day’s session, buy 25,000 to 100,000 shares of stock without putting the price up too much. Instead, he takes days, weeks or months in which to accumulate his line in one or many stocks.
Instead, here’s how he sets it up: first, he’ll “shake out” the little guys by forcing the stock lower in order to get a better price. He prefers to do this while the market is weak, dull, inactive and depressed. To the extent that they are able, he, and the other interests with whom he works, bring about the very conditions which are most favorable for accumulation of stocks at low prices. When he wishes to accumulate a line, he raids the market for that stock, makes it look very weak, and gives it the appearance of heavy liquidation by sending in selling orders through a great number of brokers. Then, he will try to time the top of his planned price rise with some “good news” about the stock he may already know about. You have often noticed that a stock will sell at the highest price for many months on the very day when a stock dividend, or some very bullish news, appears in print. This is not mere accident. The whole move is manufactured. Its purpose is to make money for inside interests — those who are operating in the stock in a large way. And this can only be done by fooling the public, or by inducing the public to fool themselve
sg, maybe I was a lil hasty with that comment. It obviously is a very important issue and as they revealed the SEC requested a lot of documentation. Again I wont be surprised if it takes longer than they estimated but perhaps you are correct in that they padded the estimated time. Hopefully we'll find out soon.
This is a huge opportunity that they can hit out of the park. There is much activity and talk about increasing insurance coverage for IVF. Having an option at half the cost w/ equivalent success rates makes it much more palatable for insurance companies.
I have to disagree with the late May to report financials. They said June which to me means end of June at best and wouldn't be surprised if it goes beyond that. The materials the SEC requested were not on the light side and again, the past doesn't really matter here. I would understand those efforts taking a back seat to other more important tasks such as developing clinic partnerships, etc.
I'm not sure if you realize what this product is all about. Of course many couples can choose to go with IVF which is much more expensive. The whole point of this product is to bring "affordable" IVF to the masses for those millions of couples who CANNOT afford $12,000 or more per treatment with a product that has already shown equivalent rates to traditional IVF. It just took the FDA forever and a day to come around to that conclusion and finally give them clearance.
The most recent Invaron / CARE trial is not the only trial that has been performed. Prior to this INVO submitted various results to the FDA ...
Even though we have more than proven the efficacy and safety of the INVOcell with its ability to assist couples in having a child, every country needs to “prove” it for themselves within their own population. It is one of the hurdles and steps we must go through to gain acceptance in each market. On a very positive note, as we continue to expand we believe we have helped over 500 couples in having babies during the past few years.
450 procedures done in Colombia, Peru, Bolivia and Brazil.
The combined results of the submitted procedures for woman across all age groups from their 20s to there 40s are: 148 clinical pregnancies equaling a 33% efficacy rate, 21 (14%) multiple births and 127 healthy babies born to date.
Dr. Elkin Lucena of CECOLFES in Columbia presented the data from a 172 cycle mild stimulation protocol INVO clinical study with ICSI (Intra Cytoplasmic Sperm Injection) for severe male factor. He obtained a 40% clinical pregnancy rate, his poster presentation is on our website. The INVOcell and Intra-Vaginal Culture process was extremely well received by the Assisted Reproduction Community and by ASRM who has endorsed the INVOcell as a lower cost alternative to IVF
btw, I also said that these levels in my opinion are excellent for someone with a long-term horizon rather than someone looking for a quick buck based on buy-out hopes.
I have all my shares Feoli, I never said I sold any. I just pointed out that your outrageous share price calls on approval never came thru and your numerous posts about buyouts and sky-high price spikes probably misled quite a few people and set unrealistic expectations.
lol, if someone had contact with the company and provided that info they would be crazy to post it on a msg forum let alone trade on it. hopefully soon we'll have some info on sales, expenses etc when INVO completes their filings
what do you mean by a big partner? someone to finance the inventory or are you talking about additional clinics? This isn't like a drug company which will partner with a larger company to finance drug trials, etc. That's not happening here.
Additional partners will be obgyn offices, other fertility clinics, etc. That wont require INVO to give shares away at least not that I can see.
And what competitor is there to the INVOcell? Unless you are referring to traditional IVF then of course there may be those who wish to take them out.
But you are correct about one thing, logic and rational thinking is required here, that being that the chance for this to move already occurred. It came and went and you were wrong with all your buyout talk and $5-7 share price estimates.
It now comes down to good old fashioned sales numbers which will take time. That is the rational thinking that one should exercise. I said this long ago, that they were not interested in selling for a quick buck and they have shown that to be the case.
so, unless you are prepared to wait this out and have them execute on their vision, all you are doing is providing noise with the constant share price/ share volume/end-of-day guestimates. No different than when you were posting constant estimates of when the Fda would reply to INVOBioscience, of which they were all wrong by the way.
This will move when its good and ready, which wont be tomorrow, Friday or next month. Be happy that this little gem is still undiscovered and buy when you get the opportunity.
absolutely correct, its a pink sheet stock and haven't reported in several years. once this is rectified and additional news of clinic openings as well as any news on past efforts updating us on what has been going on it should start to move. We also have the potential of new country applications now that the fda has given clearance....lots of good opportunities ahead. I consider it a gift to be able to buy at these levels.
If INVO procedure can prove...??
You do realize it was given FDA clearance right? There is plenty of information on trials not just in the US but international as well.
Feoli, your math seems to be off. by my count we are looking at over 2 mos.
...our goal now is to become current with filings in June 2016.
And it IS still the beginning because now its no longer based on waiting on FDA approvals, its based on sales, clinic openings, pregnancies, live births, etc.
Face it or continue to lie to yourself and perhaps mislead many here, this is not going to be a quick rise as much as we would all like it to be.
Dr John Couvaras REI @ivfphoenix · 14m14 minutes ago
Our first #INVOcell retrieval is underway! It's a new age of advanced technology to #conceive
Dr John Couvaras REI @ivfphoenix · 27m27 minutes ago
It's an exciting day! #INVOCell retrievals back to back today! #technology #youhaveitwithinyou